High post-treatment platelet reactivity (HPPR = adenosine diphosphate [ADP] 10 M-induced platelet aggregation > 70%) identifies low responders to dual antiplatelet therapy with increased risk of recurrent cardiovascular (CV) events after stenting for non-ST elevation acute coronary syndromes (NSTE-ACS)...
Keywords: Acute coronary syndromes, stenting, platelet reactivity, periprocedural myocardial infarction
00/0000 | Thrombosis and Haemostasis, Schattauer